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Abstract
Aims. This study assessed the possibility to build a prognosis predictor, based
on microarray gene expression measures, in stage II and III colon cancer patients.
Materials and Methods. Tumour (T) and non-neoplastic mucosa (NM) mRNA
samples from 18 patients (9 with a recurrence, 9 with no recurrence) were profiled
using the Affymetrix HGU133A GeneChip. The k-nearest neighbour method was
used for prognosis prediction using T and NM gene expression measures. Six-fold
cross-validation was applied to select the number of neighbours and the number of
informative genes to include in the predictors. Based on this information, one T-
based and one NM-based predictor were proposed and their accuracies estimated
by double cross-validation. Results. In 6-fold cross-validation, the lowest num-
bers of informative genes giving the lowest numbers of false predictions (2 out of
18) were 30 and 70 with the T and NM gene expression measures, respectively.
A 30-gene T-based predictor and a 70-gene NM-based predictor were then built,
with estimated accuracies of 78 and 83%, respectively. Conclusion. This study
suggests that one can build an accurate prognosis predictor for stage II and III
colon cancer patients, based on gene expression measures, and one can use either
tumour or non-neoplastic mucosa for this purpose.
 1
Introduction 
 
Postoperative treatment of stages II and III colon cancer patients remains a highly 
debated field. For stage II patients, the question of whether adjuvant chemotherapy should be 
given or not is still unanswered. A benefit of adjuvant chemotherapy is suggested by most 
meta-analyses but it has never been proved with statistical significance (Benson et al., 2004). 
The reason is probably the lack of power of the studies; if existing, the benefits of adjuvant 
chemotherapy are probably minor and thus, a study would need to enroll thousands of patients 
to establish statistical significance. However, if such a study would show a benefit of adjuvant 
chemotherapy in stage II patients, it may not be logical to conclude that this treatment should 
be given to all patients, given that 75% are cured by surgery alone (IMPACT B2, 1999) .  
The problem for stage III patients is somewhat different. The usefulness of adjuvant 
chemotherapy has been clearly demonstrated more than 10 years ago (Moertel et al., 1990), 
but the “standard” treatment, consisting of a 6-month fluorouracil (FU)-based therapy, has 
been recently questioned (Andre et al., 2004). In the study of Andre et al. (Andre et al., 2004), 
adding oxaliplatin to the “standard” therapy was shown to improve the three-year disease-free 
survival from 73 to 79%. However, even if this improvement in survival rates is confirmed 
based on five-year follow-up, it may not be logical to conclude that the “new standard” 
adjuvant chemotherapy should include oxaliplatin, given its neurotoxicity (Cersosimo, 2005) . 
This would lead to administering to all patients oxaliplatin that would be useful for only a 
few.  
In fact, the situation is quite similar for both disease stages and includes a cost-benefit 
problem. Compared to the “standard” treatment (observation in stage II patients, FU-based 
therapy in stage III patients), a “more aggressive” treatment (adjuvant chemotherapy in stage 
II patients, oxaliplatin in stage III patients) probably benefits only a minority of patients, 
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while it has no advantages or is potentially harmful for the vast majority. The situation would 
be radically different if new and accurate prognosis factors could be identified. Being able to 
isolate a sub-group of patients with a high risk or recurrence would permit more rational 
designs of clinical studies assessing “standard” versus “more aggressive” treatment: instead of 
including all patients of a given group, these studies could only include patients with a high 
risk of recurrence, thus more likely to benefit from “more aggressive” treatment. Such an 
approach would increase power to demonstrate a statistical significance between treatments 
and would address the cost-benefit problem.   
Microarray gene expression profiling has been reported to accurately predict the prognosis of 
several malignant tumors (breast carcinomas (Van de Vijver et al., 2002; Van’t Veer et al., 
2002), lung carcinomas (Bhattacharjee et al., 2001; Beer et al., 2002), lymphomas 
(Rosenwald et al., 2002; Shipp et al., 2002). Thus, by analogy with these tumors, it may be 
postulated that gene expression profiling represents a valuable tool in predicting the prognosis 
of stage II and III colon cancer patients and thereby in identifying a subgroup of patients at 
high risk of recurrence. Microarray gene expression studies in colorectal cancer have so far 
shown the possibility to distinguish between normal and tumor tissue samples, between 
different stages of disease, and between different tumor locations (left-sided versus right-
sided) (Alon et al., 1999; Backert et al., 1999; Hedge et al., 2001; Kitahara et al., 2001; 
Notterman et al., 2001; Agrawal et al., 2002; Birkenkamp-Demtroder et al., 2002; Iacopetta 
B, 2002; Lin et al., 2002; Zou et al., 2002; Fredericksen et al., 2003; ; Tureci et al., 2003; 
Williams et al., 2003; Bertucci et al., 2004). The issue of prognosis was only recently 
addressed, with promising results (Bertucci et al., 2004; Wang et al., 2004). 
The present study aimed to assess the possibility to build a prognosis predictor for 
both stage II and III colon cancer patients, based on microarray gene expression measures. In 
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contrast to the two aformentioned studies, non-neoplastic mucosa, as well as tumor, gene 
expression profiles were considered. 
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Materials and Methods 
 
Patients and samples 
 
Eighteen patients operated on for a colonic adenocarcinoma in the Department of Digestive 
Surgery of the Hospital Tenon between 1995 and 1998 were included in this study. There 
were 8 women and 10 men, with a mean age of 71 years (extremes: 39-87). None of these 18 
patients had distant metastasis at the time of surgery. Ten patients had no lymph node 
metastasis (stage II) and did not receive any adjuvant chemotherapy. The other 8 patients had 
lymph node metastasis (stage III) and received a 6-month FU-based adjuvant chemotherapy. 
Patients were evaluated at 3-month intervals for the first postoperative year and at 6-month 
intervals thereafter. Metastatic reccurrences were identified by clinical examination, 
completed by chest X-ray and liver ultrasound (or CT scan). Nine of the 18 patients 
developped a distant metastasis in the follow-up (5 stage II patients and 4 stage III patients), 
while the other 9 patients remained disease-free for at least 60 months.   
For each patient, tumor and adjacent non-neoplastic colon tissue samples were collected at the 
time of surgery, with patients’ informed consent, and were stored in liquid nitrogen within 0.5 
hour after the resection. Non-neoplastic tissue samples were collected at a distance greater 
than 5 cm from the gross tumor limit with a careful dissection of the mucosa from the deeper 
layers. Samples were reviewed by a pathologist to check the absence of tumor cells in non-
neoplastic mucosa samples and the presence of at least 80% tumor cells in tumor samples. 
 
Total RNA was extracted from the 36 samples (18 tumor and 18 non-neoplastic mucosa 
samples) using Trizol reagent. Targets were hybridized to Affymetrix HGU133A GeneChips, 
containing a total of 22,283 probe-sets (Affymetrix, Santa Clara, CA), as described in the 
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Affymetrix GeneChip Expression Analysis Manual (Affymetrix, Wooburn Green, UK). 
Briefly, 5 µg (100 ng/µl) of total RNA was used to synthesize double-stranded cDNA with 
SuperScript II reverse transcriptase (Invitrogen, Cergy Pontoise, France) and a T7-(dT)24 
primer (Proligo Biochemie GmbH, Hamburg, Germany). Then, biotinylated cRNA was 
synthesized from the double-stranded cDNA using the RNA Transcript Labeling kit (Enzo 
Life Sciences, Farmingdale, NY) and was purified and fragmented. The fragmented cRNA 
was hybridized to the oligonucleotide microarrays, which were washed and stained with 
streptavidin-phycoerythrin. Scanning was performed with a GeneArray Scanner Update 
(Affymetrix, Wooburn Green, UK). 
 
Statistical methods 
 
Pre-processing 
Starting from the 36 CEL files, gene expression measures were computed using the Robust 
Multichip Average (RMA) method described in Irizarry et al. (Irizarry et al., 2003) and 
implemented in the Bioconductor R package affy. This method includes the following 
successive steps : 1) Backgroung correction; 2) Probe-level quantile normalization; 3) 
Calculation of expression measures using median polish.  
Two genes x patients matrices of expression measures were constituted including, 
respectively, for each patient the gene expression measures in tumor samples and the gene 
expression measures in non-neoplastic mucosa samples. In the remainder of the article, we 
refer to the resulting two datasets as Tumor (T) and Non-neoplastic mucosa (NM), 
respectively.    
 
Prognosis prediction 
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The prognosis prediction method consists of the following two steps. 
a) Selection of informative genes. Genes that are differentially expressed between patients 
who experienced a tumour relapse and patients who remained disease-free are identified 
based on two-sample t-statistics with equal variance. The m genes with the largest absolute t-
statistics are retained to build a prognosis predictor. 
b) Prognosis prediction. The k-nearest neighbor method, based on the Euclidean distance 
between the expression profiles for the m informative genes of step a), is applied to predict 
prognosis. Specifically, the prognosis of a given patient is predicted as the most common 
prognosis among its k nearest neighbors, i.e., the k patients with the closest expression 
profiles.  
 
Selection of prognosis predictor parameters 
For each dataset (T and NM), 6-fold cross-validation was used to select the two 
prognosis predictor parameters, namely the number of informative genes m and the number of 
nearest neighbors k. A total of 150 prognosis predictors were considered, corresponding to the 
following parameter values: k = 1, 3, and 5, and m = 5, 10, …, 250. The performance of a 
given prognosis predictor, indexed by the pair (m,k), was assessed as follows. The 18 samples 
were divided into 6 sets of 3 samples. Each of these 6 sets was used in turn as the validation 
set; the prognosis predictor was built using the training set formed by the remaining 15 
samples and used to assign a prognosis (recurrence or no recurrence) to the 3 validation 
samples; the predicted prognoses were then compared to the actual recurrence status; the 
numbers of false predictions (discordance between the predicted and actual evolutions) and 
true predictions were recorded for each of the 18 samples. Thus, for each of the 150 prognosis 
predictors, i.e., each (m,k) pair, a prediction error rate (out of 18) was obtained. 
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Proposition of a  prognosis predictor 
For each dataset (T and NM), because of ties in the error rates in 6-fold cross-
validation, the number of informative genes of the proposed predictor was set to be the lowest 
number of informative genes, giving the lowest number of false predictions. Selection of 
informative genes was based on all 18 samples.      
 
Estimation of the generalization error of the prognosis predictor 
 A double or nested cross-validation scheme was used to assess the performance of the 
proposed T and NM prognosis predictors. For the “outer level” of cross-validation, the 18 
samples were divided into 3 sets of 6 samples (3-fold cross-validation). Each of these 3 sets 
was used in turn as the test set, the other 2 sets (12 patients) being used as the learning set. 
For each of the 3 steps in the “outer level” cross-validation, prognosis predictors (one for each 
dataset) were built based on the learning samples using the previously described method:  
i) determination of the lowest number of genes and the lowest number of nearest neighbors 
giving the lowest number of false predictions (out of 12), using 6-fold cross-validation (“inner 
level” of cross-validation); ii) selection of the m informative genes based on the 12 patients. 
The prognosis predictors were used to assign a prognosis to the 6 test samples. The predicted 
prognoses were then compared to the actual recurrence status, giving a false prediction rate 
(out of 6). The 3 false prediction rates (one for each of the 3 steps of the “outer level” cross-
validation) were averaged to provide an estimate of the generalization error.            
       
Software 
The statiscal analysis was performed with the open-source software R, Version 2.0.1 
(http://cran.r-project/org), and Bioconductor packages (www.bioconductor.org). The 
following R packages were used : affy Version 1.5.8 (Irizarry RA, Gautier L, Bolstad BM, 
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Miller C), annaffy Version 1.0.11 (Smith CA), class Version 7.2.11 (Venables T, Ripley B, 
Hornik K, Gebhardt A), hgu133a Version 1.6.5 (Zhang J) and multtest Version 1.5.2 (Pollard 
KS, Ge Y, Dudoit S). 
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Results 
 
Selection of prognosis predictor parameters 
For each dataset (T and NM), a total of 150 prognosis predictors (50 possible values for the 
number m of informative genes, 3 possible values for the number k of nearest neighbors) were 
considered and their performance assessed using 6-fold cross-validation. The distributions of 
the numbers of false predictions obtained with each of these 150 predictors are given in 
Figure 1. Results were quite similar for non-neoplastic mucosa and tumor-based predictors: 
no pair of parameters (m, k) allowed a perfect concordance between the predicted and the 
observed evolutions; the numbers of false predictions ranged between 2 and 4; two false 
predictions (out of 18, accuracy = 89%) represented the most frequent result (108 out of 150 
predictors, 72%, with NM; 84 out of 150 predictors, 56%, with T). Figure 2 shows the 
numbers of false predictions as a function of both parameters m and k. With the NM dataset, 
predictors built with 65 or fewer informative genes yielded 3 and 4 false predictions; 
predictors built with more than 70 informative genes yielded stable results (2 false 
predictions); the lowest number of informative genes giving the lowest number of false 
predictions (2 out of 18) was m=70 (with k = 3 neighbors). With the T dataset, predictors built 
with 25 or fewer informative genes yielded 3 false predictions, whatever the number of 
nearest neighbors; predictors built with more than 30 informative genes yielded 2 false 
predictions with k=3 and 5 neighbors, and 3 or 4 false predictions with k=1 neighbor; the 
lowest number of informative genes giving the lowest number of false predictions (2 out of 
18) was m=30 (with k = 3 neighbors).   
   
Proposition of a  prognosis predictor 
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Based on the results of the 6-fold cross-validation, two prognosis predictors were 
proposed. The first predictor, based on the NM expression profiles of all 18 patients, was built 
by selecting the 70 genes with largest absolute t-statistics. Of these genes, 35 were over-
expressed in patients who developed a recurrence, while the other 35 were over-expressed in 
patients who remained disease-free for at least 5 years. Both lists of genes are given in Table 
1. Informative genes can be divided into three categories:  
1) plasma membrane receptors (guanine nucleotide binding protein, lysosomal-
associated membrane protein,  tumor necrosis factor superfamily member 6, prostanglandin 
E receptor 2, interleukin 1 receptor, peptide YY, a disintegrin and metalloproteinase domain 
28, glucagon) with members of different signaling pathways (serine/threonine kinase 25, 
casein kinase 1, tyrosine kinase 2, transducin-like enhancer of split 2, member T2 of ras 
homolog gene family, insulin-like growth factor 1, neufibromin 2, integral membrane protein 
2A), and transcription factors (erythroid-derived 2-like 1, zinc finger protein 36, v-jun 
sarcoma virus 17 oncogene homolog, mitochondrial transcription factor A);  
2) proteins involved in cell growth and/or maintenance (CDC2-like 10) such as 
carbohydrate or amino acid metabolism (mitochondrial F1 complex of ATP synthase H+ 
transporting, gamma-glutamyltransferase 1, member A2 of aldehyde dehydrogenase 3 family, 
adenosylmethionine decarboxylase 1, UDP-N-acetyl-alpha-D-galactosamine), protein 
biosynthesis (transport (sorting nexin 4) and degradation (carboxypetidase A3);   
3) proteins involved in the immune response (T cell immune regulator 1, microtubule-
associated protein RP/EB family) .   
Similarly, to build the tumor-based predictor, informative genes were selected using all 18 
patients, by taking the 30 genes with the largest absolute t-statistics. Of these genes, 16 were 
over-expressed in patients who developed a recurrence, while the other 14 were over-
expressed in patients who remained disease-free for at least 5 years. Both lists of genes are 
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given in Table 2. Genes over-expressed in the tumors of patients who recurred coded for 
proteins involved in nucleic acid and protein metabolism (a member of COP9 family, member 
Z of H2A histone family, SRB7 suppressor of RNA polymerase B, v-yes-1, stress 70 protein 
chaperone, CDC28 protein kinase regulatory subunit 1B, dynactin 3, DnaJ/Hsp40 homolog, 
mitochondrial ribosomal protein L24, APG12). Also over-expressed in the tumors of patients 
who recurred were genes coding for proteins of the extracellular matrix (e.g., matrix 
metalloproteinase 12), and proteins of the immune response (e.g., interleukin 8).  
 
Estimation of the generalization error of the prognosis predictor 
The results of the double cross-validation are summarized in Table 3 (Non-neoplastic 
mucosa) and Table 4 (Tumor). In both Tables, each row gives the results of one of the 3 steps 
of the “outer level” cross-validation. For each step, 12 samples were used as the learning set, 
while the other 6 were used as the test set. In both Tables, the first set of columns indicates the 
distribution of the numbers of false predictions (out of 12) obtained with each of the 150 
predictors in the “inner level” cross-validation based on the 12 patients of the learning set. 
The second column gives the lowest numbers of informative genes and nearest neighbors that 
yielded the lowest number of false predictions for the “inner level” cross-validation (6-fold 
cross-validation). These parameter values were used to build the prognosis predictor based on 
the learning set of size 12. This predictor was then applied to assign a prognosis to each of the 
6 patients of the test set. The false prediction rates, obtained for each of the 3 steps, are given 
in the third column. The average of these 3 false prediction rates provides an estimate of the 
generalization error of the predictors. The estimate of the generalization error was 17% for the 
70-gene non-neoplastic mucosa-based predictor, and 22% for the 30-gene tumor-based 
predictor. Thus, the estimated accuracy of these two predictors was 83% and 78%, 
respectively.  
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Discussion 
 
The aim of the present study was to build a prognosis predictor that could be used, for 
both stage II and stage III colon cancer, to identify patients at high risk of recurrence and thus 
more likely to benefit from a more aggressive postoperative treatment. The statistical analysis 
was therefore performed on the combined sample of stage II and III patients but did not 
include any sub-analyses by stage of disease due to the small sample size. Patients were 
homogeneous with regard to the postoperative treatment, as they all received the current 
“standard” treatment: none of the 10 stage II patients received any adjuvant chemotherapy, 
while all 8 stage III patients received a 6-month FU-based adjuvant chemotherapy. With this 
“standard” treatment, 9 patients remained disease-free for at least 5 years and 9 developed a 
metastatic recurrence. The latter type of patients is of interest as it represents individuals who 
may potentially have benefited from a more aggressive treatment. Note that a pooled analysis 
allows us to draw a common conclusion for stage II and III patients, but does not allow any 
separate conclusions for either group.                   
 
Studies aiming to propose a predictor, for either diagnosis or prognosis purposes, are 
usually designed as follows: samples are split into a training set and a validation set; 
informative genes and possibly other prediction parameters are selected based on the training 
set, using some arbitrary rule; the resulting predictor is assessed on the validation set. The 
design of the present study, which includes two distinct rounds of cross-validation with 
different aims, deserves further discussion. The first part concerns the selection of a predictor, 
while the second aims to estimate the generalization error of the selected predictor. The k-
nearest neighbor classifier was chosen because it has been shown to be competitive with more 
complex approaches, such as aggregated classification trees and support vector machines 
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(Dudoit et al., 2003; Dudoit and Fridlyand, 2003). The main parameters of this classifier, 
namely the numbers of informative genes m and nearest neighbors k, were not chosen a-priori 
but using cross-validation in the first part of the study.  
For both types of predictors (non-neoplastic mucosa and tumor-based), 150 different 
pairs of parameters were considered and the performance of the corresponding predictors was 
assessed using 6-fold cross-validation. While this first part mainly aimed to select the 
predictor parameters, it also yielded information about the stability of non-neoplastic mucosa 
and tumor-based prognosis predictors, i.e., the sensitivity of prediction error to the parameters 
(m,k).  
Based on results of the first cross-validation, two prognosis predictors (a 30-gene 
tumor-based predictor and a 70-gene non-neoplastic mucosa-based predictor) were built on 
the whole set of patients. When proposing a predictor, it is important to provide an estimate of 
its accuracy. As a second set of independent samples was not available, a double cross-
validation design was used, with an “inner level” 6-fold cross-validation for parameter 
selection and an “outer level” 3-fold cross-validation for performance assessment of the 
selected predictor. In order to obtain an honnest estimate of generalization error, it is crucial 
that all aspects of predictor selection be included in the cross-validation process. Thus, for 
each of the 3 steps of the “outer level” cross-validation, we reproduced exactly what had been 
done in the first part of the study with an “inner level” cross-validation: i) selection of the 
parameters (m, k) yielding the best results by 6-fold cross-validation, ii) use of this 
information to build a predictor based on the 12 learning set patients. Note that the estimate of 
the generalization error, obtained by averaging the error estimates of the “outer level” cross-
validation, should be conservative, since it is computed based on sets of 12 patients (instead 
of 18). This suggests that the accuracy of the proposed predictors is not over-estimated.  
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 The results of the present study clearly suggest the possibility to build an accurate 
prognosis predictor for both stage II and III colon cancer patients based on microarray gene 
expression measures. This first conclusion supports the findings of two previous reports, even 
though different colon cancer subtypes were considered. The study of Bertucci et al. (Bertucci 
et al., 2004), which comprised all stages of disease, identified a gene set that separated 
patients with significantly different 5-year survival and suggested the relative closeness of 
tumor gene expression profiles in patients with synchronous metastases and in those with 
metachronous metastases. The study of Wang et al. (Wang et al., 2004), which focussed on 
stage II colon cancer, identified a 23-gene signature that predicted prognosis with 78% 
accuracy (the same accuracy as that of our 30-gene tumour-based predictor). Thus, it appears 
more and more likely that microarray gene expression profiling will prove to be a valuable 
tool to predict the prognosis of colon cancer patients, as previously suggested for other types 
of cancer (Bhattacharjee et al., 2001; Beer et al., 2002; Rosenwald et al., 2002; Shipp et al., 
2002; Van de Vijver et al., 2002; Van’t Veer et al., 2002). 
  
 The main finding of our study is the possibility to build a prognosis predictor based 
on either tumor or non-neoplastic mucosa gene expression profiles. To our knowledge, the 
issue of profiling non-neoplastic tissue surrounding the tumour for prognosis purpose has 
never been addressed before, neither for colorectal cancer nor for other types of solid 
tumours. The idea of studying the non-neoplastic mucosa was suggested by growing evidence 
that phenomena in cancer are not confined to tumour cells but also involve adjacent cells 
(“microenvironment theory”). There is an increasing evidence that interactions between 
stromal and cancer cells are a prerequisite for metastases to occur (Mueller and Fusenig, 
2004). However, it remains unclear whether this metastatic potential originates in cancer cells 
and/or in stromal compartments. Metastatic potential may be present from the origin of the 
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tumour (Bernards and Weinberg, 2002; Ramaswamy et al., 2003). Hence, non-neoplastic 
mucosa on which the tumor has arisen may contain some helpful information. This hypothesis 
is supported by a recent study in which several genes involved in human colon cancer were 
shown to have an altered expression in the morphologically normal colonic mucosa (Chen et 
al., 2004).  
 
The question of whether one should build a prognosis predictor based on tumor or 
non-neoplastic mucosa gene expression profiles immediately arises. The estimated accuracy 
of the 70-gene non-neoplastic mucosa-based predictor was greater than that of the 30-gene 
tumor-based predictor (83 versus 78%). However, given the limited sample size, this 
difference is not sufficient to conclude to the superiority of the non-neoplastic mucosa. Useful 
information can be drawn from the cross-validation selection part of the study regarding the 
stability of both predictors, i.e., their sensitivity to changes in parameter values. At first sight, 
results observed with both predictors may appear equivalent: the range of false predictions 
was the same (2 to 4) and the percentages of predictors yielding 2 or 3 false predictions were 
very close (95 and 98% for non-neoplastic mucosa- and tumor-based predictors, respectively). 
However, when considering the distribution of the numbers of false predictions as a function 
of the numbers of  informative genes  m and neighbors k, the tumor and non-neoplastic 
mucosa predictors exhibit a different behavior. With non-neoplastic mucosa-based predictors, 
three and four false predictions were only observed with predictors built with fewer than 65 
informative genes; with predictors built with 70 or more informative genes, error rates seemed 
to stabilize, i.e., they were not influenced by changes in either the number of genes m or the 
number of neighbors k. A similar zone of stability was not observed with tumor-based 
predictors. With k=1 nearest neighbor, the numbers of false predictions varied with the 
number of informative genes; likewise, for a given number of informative genes, error rates 
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were influenced by the number of nearest neighbors. This higher stability of non-neoplastic 
mucosa-based predictors represents an argument in favor of their use. Non-neoplastic mucosa 
samples are homogeneous while tumor samples include both cancer and stromal cells. Thus, it 
is possible that differences in stability between the two types of predictors simply reflect this 
difference in tissue homogeneity. In the present study, laser-capture microdissection was not 
used. This technique could have possibly yielded more stable results for tumor-based 
predictors. However, laser-capture microdissection cannot be considered as a routine 
technique, for reasons of cost, time, and technical difficulties. Hence, in addition to their 
possibly higher accuracy, NM-based predictors have practical advantages over T-based 
predictors.  
 
While our results may not conclusively establish the superiority of NM-based 
predictors, they do emphasize the potential usefulness of the non-neoplastic mucosa in 
predicting the prognosis of stage II and III colon cancer patients. Such a finding is not really 
surprising since there is growing evidence that the tumour microenvironment, largely 
orchestrated by inflammatory cells, is involved in the neoplastic process, fostering cell 
proliferation, survival, and migration (Mueller and Fusenig, 2004). Genetic or gene 
expression changes could occur without altering the DNA sequence and explain how stromal 
cells escape the normally growth-inhibitory effects and become willing partners in enhancing 
epithelial tumor progression. Accordingly, we have observed in tumors the over-expression of 
stromal cell genes previously reported to play a major role in the tumor migration (e.g., matrix 
metalloproteinase 12 and interleukin 8). The over-expression of members of these gene 
families has been observed in most of the gene expression profile studies of epithelial tumors 
associated with a metastatic potential. These genes play a particularly crucial role in 
carcinogenesis, since an increased expression in the mammary gland of the extra-cellular 
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matrix-degrading enzyme, matrix metalloproteinase-3, has been shown to be sufficient to 
induce mammary tumors (Sternlicht et al., 1999). As in previous gene expression studies on 
colon tumors, a significant change in the expression of gene families coding for proteins 
involved in carbohydrate metabolism, in ATP biosynthesis, in cell cycle and mitosis, and in 
protein synthesis such as those coding for ribosomal proteins, has been also observed.  
Numerous genes involved in signalling pathways were found to be over-expressed in the non-
neoplastic mucosa of patients who remained disease-free and who recurred, suggesting the 
possibility of a cross-talk between “normal” cells distant from the tumor and tumoral cells. 
Indeed, these genes included some coding for membrane receptors (e.g., tumor necrosis factor 
receptor 6 (TNFR6), prostanglandin E receptor 2, interleukin 1 receptor (IL1R)) and others 
coding for proteins involved in signalling cascades (most of them involved in the MAPK, Jak-
STAT, and Wnt signalling pathways). The role of these signalling pathways has been 
previously reported in other studies of gene expression in colorectal tumors. Thus, the cross-
talk, previously shown between stromal and cancer cells, could be relayed in the non-
neoplastic mucosa far from the primary tumor. Similarly, the concept that inflammation is a 
crucial component of tumor progression could play a major role from afar the tumor. Indeed, 
the over-expression of membrane receptors such as TNFR6, prostanglandin E receptor 2, and 
IL1R supports this hypothesis. As also expected, an over-expression of genes coding for  
proteins implicated in immune surveillance has been found. Thus, our results favour a view in 
which the apparently normal tissue in which a tumor appears and develops may contain or 
acquire information on the ability of this tumor to further invade and disseminate. The control 
exerted by non-tumoral tissue on neoplastic lesion formation may be part of the homeostatic 
tissue functions that may be either genetically “weak” or altered by continuous chemical or 
inflammatory aggressions. 
 
Hosted by The Berkeley Electronic Press
 18
 In conclusion, the present study suggests the possibility to build an accurate prognosis 
predictor using gene expression profiles for stage II and III colon cancer patients. More 
remarkably, it suggests that such a predictor may be based on either the non-neoplastic 
mucosa or the tumor gene expression profiles. The study also raises questions regarding the 
role of the “normal mucosa” surrounding the tumor. 
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Table 1. Differentially expressed genes in non-neoplastic mucosa samples. 
 
 
Over-expressed genes in patients who developed a recurrence 
Affy  
Probe ID 
Gene Name GenBank 
Accession Number 
213415_at 
220442_at 
207080_s_at 
205997_at 
204697_s_at 
202889_x_at 
206121_at 
220622_at 
209541_at 
204674_at 
204781_s_at 
206631_at 
202742_s_at 
212652_s_at 
204207_s_at 
219747_at 
211372_s_at 
217251_x_at 
208284_x_at 
201988_s_at 
210544_s_at 
201196_s_at 
210767_at 
206422_at 
218374_s_at 
203176_s_at 
219036_at 
201805_at 
205624_at 
202501_at 
201768_s_at 
208870_x_at 
 
202746_at 
210951_x_at 
209515_s_at 
Chloride intracellular channel 2 
UDP-N-acetyl-alpha-D-galactosamine 
peptide YY 
a disintegrin and metalloproteinase domain 28 
chromogranin A (parathyroid secretory protein 1) 
microtubule-associated protein 7 
adenosine monophosphate deaminase 1 (isoform M) 
hypothetical protein FLJ23259 
insulin-like growth factor 1 (somatomedin C) 
lymphoid-restricted membrane protein 
tumor necrosis factor receptor superfamily, member 6 
prostaglandin E receptor 2 (subtype EP2), 53kDa 
protein kinase, cAMP-dependent, catalytic, beta 
sorting nexin 4 
RNA guanylyltransferase and 5'-phosphatase 
hypothetical protein FLJ23191 
interleukin 1 receptor, type II 
 
gamma-glutamyltransferase 1 
cAMP responsive element binding protein-like 2 
aldehyde dehydrogenase 3 family, member A2 
adenosylmethionine decarboxylase 1 
neurofibromin 2 (bilateral acoustic neuroma) 
glucagon 
chromosome 12 open reading frame 4 
transcription factor A, mitochondrial 
p10-binding protein 
protein kinase, AMP-activated, gamma 1 non-catalytic subunit 
carboxypeptidase A3 (mast cell) 
microtubule-associated protein, RP/EB family, member 2 
enthoprotin 
ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
integral membrane protein 2A 
RAB27A, member RAS oncogene family 
RAB27A, member RAS oncogene family 
AI768628 
NM_003774 
NM_004160 
NM_021778 
NM_001275 
T62571 
NM_000036 
NM_024727 
AI972496 
NM_006152 
NM_000043 
NM_000956 
NM_002731 
AA524345 
AB012142 
NM_024574 
U64094 
AF043583 
NM_013421 
BF438056 
BC002430 
M21154 
BC003112 
NM_002054 
NM_020374 
BE552470 
NM_024491 
NM_002733 
NM_001870 
NM_014268 
BC004467 
BC000931 
 
AL021786 
AF125393 
U38654 
Over-expressed genes in patients who remained disease-free 
Affy 
Probe ID 
Gene Name GenBank 
Accession Number 
212212_s_at 
33132_at 
214494_s_at 
201464_x_at 
201314_at 
212796_s_at 
211996_s_at 
217223_s_at 
221899_at 
DKFZP586J0619 protein 
cleavage and polyadenylation specific factor 1, 160kDa 
 
v-jun sarcoma virus 17 oncogene homolog (avian) 
serine/threonine kinase 25 (STE20 homolog, yeast) 
KIAA1055 protein 
 
split hand/foot malformation (ectrodactyly) type 3 pseudogene 1 
phosphonoformate immuno-associated protein 5 
BF055496 
U37012 
NM_005200 
BG491844 
NM_006374 
BF195608 
BG256504 
U07000 
AI809961 
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201480_s_at 
220762_s_at 
 
219053_s_at 
202573_at 
201553_s_at 
222210_at 
217931_at 
200759_x_at 
205546_s_at 
200799_at 
203317_at 
210622_x_at 
222219_s_at 
212280_x_at 
203469_s_at 
204158_s_at 
 
221214_s_at 
205583_s_at 
222131_x_at 
211962_s_at 
207743_at 
203624_at 
 
201466_s_at 
215235_at 
221800_s_at 
37028_at 
suppressor of Ty 5 homolog (S. cerevisiae) 
guanine nucleotide binding protein (G protein), beta polypeptide 
1-like 
hypothetical protein FLJ20847 
casein kinase 1, gamma 2 
lysosomal-associated membrane protein 1 
CASK interacting protein 2 
trinucleotide repeat containing 5 
nuclear factor (erythroid-derived 2)-like 1 
tyrosine kinase 2 
heat shock 70kDa protein 1A 
pleckstrin and Sec7 domain containing 4 
cyclin-dependent kinase (CDC2-like) 10 
transducin-like enhancer of split 2 (E(sp1) homolog, Drosophila) 
APG4 autophagy 4 homolog B (S. cerevisiae) 
cyclin-dependent kinase (CDC2-like) 10 
T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal 
V0 protein a isoform 3 
nasal embryonic LHRH factor 
hypothetical protein FLJ23018 
ras homolog gene family, member T2 
zinc finger protein 36, C3H type-like 1 
PRO1880 protein 
DNA segment on chromosome X and Y (unique) 155 expressed 
sequence 
v-jun sarcoma virus 17 oncogene homolog (avian) 
spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 
hypothetical protein FLJ22175 
protein phosphatase 1, regulatory (inhibitor) subunit 15A 
NM_003169 
NM_022446 
 
NM_017966 
AL530441 
NM_005561 
AK025262 
BC004423 
NM_003204 
NM_003331 
NM_005345 
NM_012455 
AF153430 
AC007766 
AA532726 
NM_003674 
NM_006019 
 
NM_015537 
NM_024810 
BC004327 
BG250310 
NM_014104 
NM_005088 
 
NM_002228 
AL110273 
AA551370 
U83981 
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Table 2. Differentially expressed genes in tumor samples. 
 
 
Over-expressed genes in patients who developed a recurrence 
Affy 
Probe ID 
Gene Name GenBank 
Accession Number 
204580_at 
208737_at 
 
218042_at 
 
200853_at 
211506_s_at 
209362_at 
210754_s_at 
202558_s_at 
200096_s_at 
201897_s_at 
204246_s_at 
202842_s_at 
218919_at 
218270_at 
213026_at 
210907_s_at 
matrix metalloproteinase 12 (macrophage elastase) 
ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G 
isoform 1 
COP9 constitutive photomorphogenic homolog subunit 4 
(Arabidopsis) 
H2A histone family, member Z 
interleukin 8 
SRB7 suppressor of RNA polymerase B homolog (yeast) 
v-yes-1 Yamaguchi sarcoma viral related oncogene homolog 
stress 70 protein chaperone, microsome-associated, 60kDa 
ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e 
CDC28 protein kinase regulatory subunit 1B 
dynactin 3 (p22) 
DnaJ (Hsp40) homolog, subfamily B, member 9 
hypothetical protein FLJ14007 
mitochondrial ribosomal protein L24 
APG12 autophagy 12-like (S. cerevisiae) 
programmed cell death 10 
NM_002426 
BC003564 
 
NM_016129 
 
NM_002106 
AF043337 
AI688580 
M79321 
NM_006948 
AI862255 
NM_001826 
NM_007234 
AL080081 
NM_024699 
NM_024540 
BE965998 
BC002506 
Over-expressed genes in patients who remained disease-free 
Affy 
Probe ID 
Gene Name GenBank 
Accession Number 
215364_s_at 
204535_s_at 
209446_s_at 
222252_x_at 
213155_at 
217586_x_at 
202032_s_at 
219516_at 
 
220505_at 
209848_s_at 
205451_at 
 
203995_at 
207499_x_at 
207863_at 
KIAA0467 protein 
RE1-silencing transcription factor 
hypothetical protein FLJ10803 
chromosome 1 open reading frame 6 
KIAA0523 protein 
 
mannosidase, alpha, class 2A, member 2 
transient receptor potential cation channel, subfamily V, 
member 4 
chromosome 9 open reading frame 53 
silver homolog (mouse) 
myeloid/lymphoid or mixed-lineage leukemia (trithorax 
homolog, Drosophila),  translocated to, 7 
chromosome 21 open reading frame 2 
 
ADP-ribosylarginine hydrolase 
AB007936 
AI978576 
BC001743 
AK023354 
AB011095 
N35922 
NM_006122 
NM_021625 
 
NM_016349 
U01874 
NM_005938 
 
NM_004928 
NM_017979 
NM_001125 
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Table 3. Results of the double cross-validation. Non-neoplastic mucosa. 
 
 
Inner level 6-fold CV, 
number of predictors with 
Step in 
outer level 
3-fold CV 1 FP * 2 FP * 3 FP * 4 FP * 
Parameters selected 
in inner level CV 
(m,k) 
FP Rate on outer 
level CV test set 
Step 1 129 18 3  m = 40 , k = 1 1/6 
Step 2  57 91 2 m = 15 , k = 3 1/6 
Step 3  12 85 53 m = 70 , k = 5 1/6 
17% ** 
 
 
FP: False prediction 
CV: Cross-validation 
*: Out of 12 samples, for inner level 6-fold cross-validation 
**: Generalization error, out of 18 samples, for outer level 3-fold cross-validation 
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Table 4. Results of the double cross-validation. Tumor. 
 
 
Inner level 6-fold CV, 
number of predictors with 
Step in 
outer level 
3-fold CV 0 FP * 1 FP * 2 FP * 3 FP * 4 FP * 
Parameters 
selected in inner 
level CV (m,k) 
FP Rate on 
outer level 
CV test set 
Step 1  3 146 1  m = 10 , k = 1 2/6 
Step 2 65 77 8   m = 5 , k = 1 1/6 
Step 3    106 44 m = 35 , k = 1 1/6 
22% ** 
 
 
FP: False prediction 
CV: Cross-validation 
* : out of 12 samples, for inner level 6-fold cross-validation 
**: generalization error, out of 18 samples, for outer level 3-fold cross-validation 
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Figure 1. Distributions of the numbers of false predictions. 
 
 
 
For each dataset (non-neoplastic mucosa and tumor datasets), a total of 150 prognosis 
predictors - 50 possible values for the number m of informative genes (m = 5, 10, …, 250), 3 
possible values for the number k of nearest neighbors (k = 1, 3, and 5) - were considered and 
their performance assessed using 6-fold cross-validation. Figure 1 shows the distribution of 
the numbers of false predictions (out of 18) obtained with each of these 150 predictors. 
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Figure 2. Number of false predictions. 
 
 
 
Figure 2 shows, for each dataset (non-neoplastic mucosa and tumor datasets), the numbers of 
false predictions as a function of the number m of informative genes (x-axis) and the number 
k of nearest neighbors (y-axis). In these pseudo-color images, colored rectangles indicate the 
number of false predictions, with yellow (red) corresponding to the lowest (highest) numbers 
of errors.  
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